A review of dupilumab in the treatment of atopic diseases

References

• Us fda. Dupixent® (dupilumab) injection, for subcutaneous use: us prescribing information; 2017 [ accessed 2018 Nov 12]. https://www.Fda.Gov.
   Google Scholar
• Swain SL, Weinberg AD, English M, Huston G. Il-4 directs the development of th2-like helper effectors. J Immunol. 1990;145:3796–806.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111(1 Suppl):S18–34; discussion S34–16. doi:10.1067/mai.2003.25.
   PubMedGoogle Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the il-4/il-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–37. doi:10.1080/1744666X.2017.1298443.
   PubMed Web of Science ®Google Scholar
• Bhardwaj R, Suzuki A, Leland P, Joshi BH, Puri RK. Identification of a novel role of il-13ralpha2 in human glioblastoma multiforme: interleukin-13 mediates signal transduction through ap-1 pathway. J Transl Med. 2018;16(1):369. doi:10.1186/s12967-018-1746-6.
   PubMedGoogle Scholar
• Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA. 2016;315(5):469–79. doi:10.1001/jama.2015.19330.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96. doi:10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi:10.1016/S0140-6736(15)00388-8.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85. doi:10.1056/NEJMoa1804093.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48. doi:10.1056/NEJMoa1610020.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Jan;143(1):155–172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5.
   Web of Science ®Google Scholar
• Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019 Jan;80(1):158–167.e1. doi: 10.1016/j.jaad.2018.07.048. Epub 2018 Aug 6.
   PubMedGoogle Scholar
• Kovalenko P, DiCioccio AT, Davis JD, Li M, Ardeleanu M, Graham N, Soltys R. Exploratory population pk analysis of dupilumab, a fully human monoclonal antibody against il-4ralpha, in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol. 2016;5(11):617–24. doi:10.1002/psp4.12136.
   PubMedGoogle Scholar
• Davis JD, Bansal A, Hassman D, Akinlade B, Li M, Li Z, Swanson B, Hamilton JD, DiCioccio AT. Evaluation of potential disease-mediated drug-drug interaction in patients with moderate-to-severe atopic dermatitis receiving dupilumab. Clin Pharmacol Ther. 2018;104(6):1146–54. doi:10.1002/cpt.1058.
   PubMed Web of Science ®Google Scholar
• DaVeiga SP. Epidemiology of atopic dermatitis: A review. Allergy Asthma Proc. 2012;33(3):227–34. doi:10.2500/aap.2012.33.3569.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Mastey V. Patient burden of moderate to severe atopic dermatitis (ad): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–98. doi:10.1016/j.jaad.2015.10.043.
   PubMed Web of Science ®Google Scholar
• Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3). doi:10.4172/2155-9899.1000110.
   PubMedGoogle Scholar
• Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–39. doi:10.1056/NEJMoa1314768.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (liberty ad chronos): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. doi:10.1016/S0140-6736(17)31191-1.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: A placebo-controlled, randomized phase iii clinical trial (liberty ad cafe). Br J Dermatol. 2018;178(5):1083–101. doi:10.1111/bjd.16156.
   PubMed Web of Science ®Google Scholar
• Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Int Immunopharmacol. 2018;54:303–10. doi:10.1016/j.intimp.2017.11.031.
   PubMed Web of Science ®Google Scholar
• Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69.e61. doi:10.1016/j.jaad.2017.09.052.
   PubMed Web of Science ®Google Scholar
• Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–11. doi:10.1001/jamadermatol.2018.2690.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegraber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778–1780.e1771. doi:10.1016/j.jaip.2018.01.034.
   PubMed Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the gina dissemination committee report. Allergy. 2004;59(5):469–78. doi:10.1111/j.1398-9995.2004.00526.x.
   PubMed Web of Science ®Google Scholar
• Adachi M, Hozawa S, Nishikawa M, Yoshida A, Jinnai T, Tamura G. Asthma control and quality of life in a real-life setting: A cross-sectional study of adult asthma patients in japan (acquire-2). J Asthma. 2018:1–10. doi:10.1080/02770903.2018.1514628.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond. Am J Respir Cell Mol Biol. 2016;55(1):1–4. doi:10.1165/rcmb.2016-0141PS.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J, Castro M. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–1581.e1573. doi:10.1016/j.jaip.2017.08.024.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (musca): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66. doi:10.1056/NEJMoa1304048.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi:10.1016/S0140-6736(16)30307-5.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya N, Gilani S. Prevalence of potential adult chronic rhinosinusitis symptoms in the united states. Otolaryngol Head Neck Surg. 2018;159(3):522–25. doi:10.1177/0194599818774006.
   PubMed Web of Science ®Google Scholar
• Rudmik L, Smith TL. Quality of life in patients with chronic rhinosinusitis. Curr Allergy Asthma Rep. 2011;11(3):247–52. doi:10.1007/s11882-010-0175-2.
   PubMed Web of Science ®Google Scholar
• Bachert C, Pawankar R, Zhang L, Bunnag C, Fokkens WJ, Hamilos DL, Jirapongsananuruk O, Kern R, Meltzer EO, Mullol J, et al. Icon: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):25. doi:10.1186/1939-4551-7-25.
   PubMedGoogle Scholar
• Schubert MS. A superantigen hypothesis for the pathogenesis of chronic hypertrophic rhinosinusitis, allergic fungal sinusitis, and related disorders. Ann Allergy Asthma Immunol. 2001;87(3):181–88. doi:10.1016/S1081-1206(10)62222-3.
   PubMed Web of Science ®Google Scholar
• Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol. 2015;11(3):349–61. doi:10.1586/1744666X.2015.1010517.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, Lin P, Bousquet J, Van Steen K. Presence of il-5 protein and ige antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010;126(5):962–968, 968.e961–966. doi:10.1016/j.jaci.2010.07.007.
   Web of Science ®Google Scholar
• Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, Schleimer RP, Ledford D. Endotypes and phenotypes of chronic rhinosinusitis: A practall document of the european academy of allergy and clinical immunology and the american academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2013;131(6):1479–90. doi:10.1016/j.jaci.2013.02.036.
   PubMed Web of Science ®Google Scholar